A comprehensive landscape analysis reveals a growing global pipeline of Natural Killer (NK) cell therapies for solid tumors, underscoring their emerging role in immuno-oncology. These therapies leverage innate immune mechanisms to target cancer cells, representing promising alternatives or complements to existing treatments with ongoing clinical trials worldwide.